Podcasts about tocagen

Host: Jenn Simmons, MD Guest: Clark C. Chen, MD, PhD Guest: David Piccioni, MD, PHD Guest: Christina I. Tsien, MD There is currently a high unmet need for treating high grade glioma, but is there hope on the horizon for more treatment alternatives? Joining Dr. Jenn Simmons to break down the current standard of care and potential treatments under investigation for high grade glioma are Dr. Clark Chen, Dr. Christina Tsien, and Dr. David Piccioni. ©2019 Tocagen. All rights reserved. VV-REG-003123 10/19

Host: Jenn Simmons, MD Guest: Clark C. Chen, MD, PhD Guest: David Piccioni, MD, PHD Guest: Christina I. Tsien, MD There is currently a high unmet need for treating high grade glioma, but is there hope on the horizon for more treatment alternatives? Joining Dr. Jenn Simmons to break down the current standard of care and potential treatments under investigation for high grade glioma are Dr. Clark Chen, Dr. Christina Tsien, and Dr. David Piccioni. ©2019 Tocagen. All rights reserved. VV-REG-003123 10/19

Host: Jenn Simmons, MD Guest: Clark C. Chen, MD, PhD Guest: David Piccioni, MD, PHD Guest: Christina I. Tsien, MD There is currently a high unmet need for treating high grade glioma, but is there hope on the horizon for more treatment alternatives? Joining Dr. Jenn Simmons to break down the current standard of care and potential treatments under investigation for high grade glioma are Dr. Clark Chen, Dr. Christina Tsien, and Dr. David Piccioni. ©2019 Tocagen. All rights reserved. VV-REG-003123 10/19

Host: Jenn Simmons, MD Guest: Clark C. Chen, MD, PhD Guest: David Piccioni, MD, PHD Guest: Christina I. Tsien, MD There is currently a high unmet need for treating high grade glioma, but is there hope on the horizon for more treatment alternatives? Joining Dr. Jenn Simmons to break down the current standard of care and potential treatments under investigation for high grade glioma are Dr. Clark Chen, Dr. Christina Tsien, and Dr. David Piccioni. ©2019 Tocagen. All rights reserved. VV-REG-003123 10/19

Moira speaks with Duke University Senior Fellow, Dan Heath, about “The Power of Moments”. It turns out, we actually remember our life in slices of time. Then on Tech Nation Health, it’s the power of viruses – against cancer. Moira speaks with Dr. Harry Gruber, the President for Science and Innovation at Tocagen about their genetically engineered viruses. Their first, glioblastoma, has received breakthrough therapy designation from the FDA. Tocagen is also working on colorectal, breast, lung, pancreatic and renal cancers, as well as melanoma. Dr. Gruber explains how the virus works.

Moira speaks with Duke University Senior Fellow, Dan Heath, about “The Power of Moments”. It turns out, we actually remember our life in slices of time. Then on Tech Nation Health, it’s the power of viruses – against cancer. Moira speaks with Dr. Harry Gruber, the President for Science and Innovation at Tocagen about their genetically engineered viruses. Their first, glioblastoma, has received breakthrough therapy designation from the FDA. Tocagen is also working on colorectal, breast, lung, pancreatic and renal cancers, as well as melanoma. Dr. Gruber explains how the virus works.

On Tech Nation Health, it’s the power of viruses – against cancer. Moira speaks with Dr. Harry Gruber, the President for Science and Innovation at Tocagen about their genetically engineered viruses. Their first, glioblastoma, has received breakthrough therapy designation from the FDA. Tocagen is also working on colorectal, breast, lung, pancreatic and renal cancers, as well as melanoma. Dr. Gruber explains how the virus works.

On Tech Nation Health, it’s the power of viruses – against cancer. Moira speaks with Dr. Harry Gruber, the President for Science and Innovation at Tocagen about their genetically engineered viruses. Their first, glioblastoma, has received breakthrough therapy designation from the FDA. Tocagen is also working on colorectal, breast, lung, pancreatic and renal cancers, as well as melanoma. Dr. Gruber explains how the virus works.